tiprankstipranks
Catalyst Pharmaceuticals sees FY24 revenue $475M-$485M, consensus $473.67M
PremiumThe FlyCatalyst Pharmaceuticals sees FY24 revenue $475M-$485M, consensus $473.67M
16d ago
CPRX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
CPRX Upcoming Earnings Report: What to Expect?
19d ago
Catalyst Pharmaceuticals price target raised to $27 from $26 at BofA
Premium
The Fly
Catalyst Pharmaceuticals price target raised to $27 from $26 at BofA
1M ago
Catalyst Pharmaceuticals price target raised to $31 from $27 at Citi
PremiumThe FlyCatalyst Pharmaceuticals price target raised to $31 from $27 at Citi
4M ago
Catalyst Pharmaceuticals backs FY24 revenue view $455M-$475M,
Premium
The Fly
Catalyst Pharmaceuticals backs FY24 revenue view $455M-$475M,
4M ago
Catalyst Pharmaceuticals reports Q2 EPS 33c, consensus 26c
Premium
The Fly
Catalyst Pharmaceuticals reports Q2 EPS 33c, consensus 26c
4M ago
Catalyst Pharmaceuticals price target raised to $26 from $24 at H.C. Wainwright
PremiumThe FlyCatalyst Pharmaceuticals price target raised to $26 from $24 at H.C. Wainwright
7M ago
Catalyst Pharmaceutical’s Buyback: A Double-Edged Sword for Financial Health and R&D Investment?
Premium
Company Announcements
Catalyst Pharmaceutical’s Buyback: A Double-Edged Sword for Financial Health and R&D Investment?
7M ago
Catalyst Pharmaceuticals reports Q1 EPS 19c, consensus 17c
Premium
The Fly
Catalyst Pharmaceuticals reports Q1 EPS 19c, consensus 17c
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100